Top

International Journal of Clinical Oncology

Published in:

01-04-2016 | Original Article

The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients

Authors: Toshiro Masuda, Masafumi Kuramoto, Shinya Shimada, Satoshi Ikeshima, Kenichiro Yamamoto, Kenichi Nakamura, Shinich Yoshimatsu, Masayuki Urata, Hideo Baba

Published in: International Journal of Clinical Oncology | Issue 2/2016

Abstract

Background

The aim of this study was to investigate the effects of extensive intraoperative peritoneal lavage (EIPL) therapy on stage III B + C and CY1/P0 gastric cancer patients after potentially curative surgery.

Methods

The study included 37 patients with CY1/P0 and 23 patients with stage III B + C gastric cancer who were treated with potentially curative gastrectomy and EIPL therapy between March 1995 and May 2013. D2 lymphadenectomy, R0 resection, and EIPL therapy were performed for all cases.

Results

Multivariate analysis revealed that male gender (P = 0.01) and lymph node metastasis (P = 0.03) were independent prognostic factors, while positive cytology was not (P = 0.21). There was no significant difference in overall survival rates between the CY1/P0 and stage III B + C groups (P = 0.93). There was also no significant difference in peritoneal recurrence rates, i.e., 13 (35.1%) in the CY1/P0 group and 5 (21.7%) in the stage III B + C group (P = 0.39).

Conclusions

EIPL therapy combined with complete resection and sufficient (D2) lymphadenectomy could improve the prognosis of CY1/P0 gastric cancer and, to a similar extent, that of stage III B + C.

Yonemura Y, Endou Y, Shinbo M et al (2009) Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol 100:311–316CrossRefPubMed

Harmon RL, Sugarbaker PH (2005) Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2:3CrossRefPubMedPubMedCentral

Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112CrossRef

Sobin L, Gospodarowicz M, Wittekind C (2009) TNM classification of malignant tumours, 7th edn. Wiley, New York

Leake PA, Cardoso R, Seevaratnam R et al (2012) A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer 15(Suppl 1):S27–S37CrossRefPubMed

Mezhir JJ, Shah MA, Jacks LM et al (2010) Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 17:3173–3180CrossRefPubMed

Marutsuka T, Shimada S, Shiomori K et al (2003) Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res 9:678–685PubMed

Shimada S, Tanaka E, Marutsuka T et al (2002) Extensive intraoperative peritoneal lavage and chemotherapy for gastric cancer patients with peritoneal free cancer cells. Gastric Cancer 5:168–172CrossRefPubMed

Yamamoto K, Shimada S, Hirota M et al (2005) EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer. Int J Oncol 27:1321–1328PubMed

10.

Ikeshima S, Kuramoto M, Shimada S et al (2013) Standard prophylactic strategy against peritoneal dissemination metastasis in gastric cancer. J Cancer Ther 4:99–103CrossRef

11.

Kuramoto M, Shimada S, Ikeshima S et al (2012) A proposal of a practical and optimal prophylactic strategy for peritoneal recurrence. J Oncol 2012:340380CrossRefPubMedPubMedCentral

12.

Kuramoto M, Shimada S, Ikeshima S et al (2009) Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 250:242–246CrossRefPubMed

13.

Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1:10–24CrossRefPubMed

14.

Fujimoto S, Takahashi M, Mutou T et al (1997) Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884–891CrossRefPubMed

15.

Gunji S, Obama K, Matsui M et al (2013) A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin. Surgery 154:991–999CrossRefPubMed

16.

Hall JJ, Loggie BW, Shen P et al (2004) Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 8:454–463CrossRefPubMed

17.

Sasako M, Sakuramoto S, Katai H et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393CrossRefPubMed

18.

Yu X, Ren Z, Xue Y et al (2013) D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer. Neoplasma 60:174–181CrossRefPubMed

19.

Matharu G, Tucker O, Alderson D (2011) Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg 98:1225–1235CrossRefPubMed

20.

Yan TD, Black D, Sugarbaker PH, Zhu J et al (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–2713CrossRefPubMed

21.

Emoto S, Yamaguchi H, Kamei T et al (2013) Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer. Surg Today 44:919–926CrossRefPubMed

Title: The effect of extensive intraoperative peritoneal lavage therapy (EIPL) on stage III B + C and cytology-positive gastric cancer patients
Authors: Toshiro Masuda
Masafumi Kuramoto
Shinya Shimada
Satoshi Ikeshima
Kenichiro Yamamoto
Kenichi Nakamura
Shinich Yoshimatsu
Masayuki Urata
Hideo Baba
Publication date: 01-04-2016
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 2/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0892-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2016

Predictive markers, including total lesion glycolysis, for the response of lymph node(s) metastasis from head and neck squamous cell carcinoma treated by chemoradiotherapy

The processus vaginalis transection method is superior to the simple prophylactic procedure for prevention of inguinal hernia after radical prostatectomy

Clinical trials of antiangiogenic therapy for hepatocellular carcinoma

Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907 trial

Growth rate of chemotherapy-naïve lung metastasis from colorectal cancer could be a predictor of early relapse after lung resection

Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer